Rapcabtagene Autoleucel for severe diffuse scleroderma
Treatments studied
Part of Skin clinical trials.
This trial tests an investigational cell therapy called rapcabtagene autoleucel for people with severe diffuse cutaneous systemic sclerosis (a type of scleroderma that affects the skin and internal organs). The treatment uses your own modified immune cells to potentially calm the disease activity.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with diffuse scleroderma (skin tightening affecting arms, legs, and trunk) within the last 7 years.
- Your disease is severe and getting worse, such as lung scarring, rapidly spreading skin thickening, or heart involvement.
- You are up to date on all recommended vaccines for people with weakened immune systems.
- You are not pregnant, and if you could become pregnant, you agree to use effective birth control as required by the study.
- You have not had any live vaccines in the last 6 weeks and you are willing to stop certain medications as needed.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new CAR-T cell therapy called relmacabtagene autoleucel for people with diffuse systemic sclerosis (scleroderma) that is not responding to standard treatments. The goal is to see if this therapy can help control the disease.
This trial tests a new CAR-T cell treatment called rapcabtagene autoleucel for people with active lupus or lupus nephritis that hasn't improved with at least two standard therapies. It aims to reduce disease activity and may offer a new option for hard-to-treat cases.
This trial tests a new cell therapy (Rapcabtagene Autoleucel) to see if it's safe and might help people with rheumatoid arthritis or Sjogren's disease who haven't responded to standard treatments.
This trial tests whether a special type of immune cell therapy, called CAR T-cells, can help people with severe systemic sclerosis (a disease causing skin and organ hardening) that hasn't improved with standard treatments. The goal is to see if it can stop the disease from getting worse.
This trial tests a new treatment called CABA-201, which uses your own immune cells to target and calm the overactive immune system causing scleroderma. It aims to reduce symptoms and slow or stop the disease's progression.
This trial tests a new cell therapy (CT1190B) for people with moderate to severe lupus or systemic sclerosis that has not responded to standard treatments. The therapy aims to calm the overactive immune system causing these autoimmune diseases.
Hear when a new Scleroderma, Diffuse trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.